$CVRX
CVRx, Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024010719 Filed on August 02, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $13.37M $11.81M
YoY Change 27.23% 24.28%
Cost Of Revenue $2.248M $1.900M
YoY Change 32.94% 25.25%
Gross Profit $11.13M $9.907M
YoY Change 26.13% 24.1%
Gross Profit Margin 83.19% 83.91%
Selling, General & Admin $21.63M $21.12M
YoY Change 38.21% 28.32%
% of Gross Profit 194.44% 213.13%
Research & Development $2.504M $2.765M
YoY Change -7.12% -15.7%
% of Gross Profit 22.51% 27.91%
Depreciation & Amortization $169.0K $141.0K
YoY Change 23.36% 11.02%
% of Gross Profit 1.52% 1.42%
Operating Expenses $24.14M $23.88M
YoY Change 31.55% 21.0%
Operating Profit -$13.01M -$13.97M
YoY Change 36.56% 18.9%
Interest Expense -$958.0K -$959.0K
YoY Change -291.98% 99.38%
% of Operating Profit
Other Income/Expense, Net $917.0K $944.0K
YoY Change -13.16% 53.25%
Pretax Income -$13.05M -$13.99M
YoY Change 45.49% 20.41%
Income Tax $47.00K $41.00K
% Of Pretax Income
Net Earnings -$13.10M -$14.03M
YoY Change 45.37% 20.41%
Net Earnings / Revenue -97.95% -118.82%
Basic Earnings Per Share -$0.57 -$0.65
Diluted Earnings Per Share -$0.57 -$0.65
COMMON SHARES
Basic Shares Outstanding 21.79M 21.60M
Diluted Shares Outstanding 22.78M 21.63M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $100.2M $70.40M
YoY Change 20.68% -22.48%
Cash & Equivalents $100.2M $70.40M
Short-Term Investments
Other Short-Term Assets $2.786M $1.762M
YoY Change -15.58% -50.27%
Inventory $11.89M $11.22M
Prepaid Expenses
Receivables $9.033M $8.606M
Other Receivables $0.00 $0.00
Total Short-Term Assets $123.9M $91.99M
YoY Change 19.57% -17.87%
LONG-TERM ASSETS
Property, Plant & Equipment $2.631M $2.763M
YoY Change 52.7% -5.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $26.00K $26.00K
YoY Change 0.0% -3.7%
Total Long-Term Assets $3.801M $3.989M
YoY Change 35.41% 34.72%
TOTAL ASSETS
Total Short-Term Assets $123.9M $91.99M
Total Long-Term Assets $3.801M $3.989M
Total Assets $127.7M $95.98M
YoY Change 19.99% -16.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.276M $3.516M
YoY Change 189.14% 19.88%
Accrued Expenses $7.671M $5.610M
YoY Change 22.27% -6.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.95M $9.126M
YoY Change 47.79% 2.25%
LONG-TERM LIABILITIES
Long-Term Debt $49.21M $29.32M
YoY Change 244.3% 105.7%
Other Long-Term Liabilities $1.378M $1.265M
YoY Change 43.54% -30.91%
Total Long-Term Liabilities $50.59M $30.58M
YoY Change 231.66% 90.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.95M $9.126M
Total Long-Term Liabilities $50.59M $30.58M
Total Liabilities $62.49M $40.73M
YoY Change 165.05% 62.87%
SHAREHOLDERS EQUITY
Retained Earnings -$526.7M -$513.6M
YoY Change 12.49% 11.84%
Common Stock $592.1M $569.1M
YoY Change 7.41% 3.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $65.18M $55.25M
YoY Change
Total Liabilities & Shareholders Equity $127.7M $95.98M
YoY Change 19.99% -16.52%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$13.10M -$14.03M
YoY Change 45.37% 20.41%
Depreciation, Depletion And Amortization $169.0K $141.0K
YoY Change 23.36% 11.02%
Cash From Operating Activities -$10.41M -$9.830M
YoY Change 28.2% -23.25%
INVESTING ACTIVITIES
Capital Expenditures $37.00K $355.0K
YoY Change -7.5% 148.25%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$37.00K -$355.0K
YoY Change -7.5% 148.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.20M 472.0K
YoY Change 11067.22% -0.21%
NET CHANGE
Cash From Operating Activities -10.41M -9.830M
Cash From Investing Activities -37.00K -355.0K
Cash From Financing Activities 40.20M 472.0K
Net Change In Cash 29.76M -9.713M
YoY Change -481.47% -22.16%
FREE CASH FLOW
Cash From Operating Activities -$10.41M -$9.830M
Capital Expenditures $37.00K $355.0K
Free Cash Flow -$10.45M -$10.18M
YoY Change 28.03% -21.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21628542
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20711850
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21430276
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20702589
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21628542
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20711850
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
dei Entity Central Index Key
EntityCentralIndexKey
0001235912
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21712357
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20879199
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40545
dei Entity Registrant Name
EntityRegistrantName
CVRx, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
41-1983744
dei Entity Address Address Line1
EntityAddressAddressLine1
9201 West Broadway Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 650
dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55445
dei City Area Code
CityAreaCode
763
dei Local Phone Number
LocalPhoneNumber
416-2840
dei Security12b Title
Security12bTitle
Common stock,
dei Trading Symbol
TradingSymbol
CVRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21785714
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70400000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90569000
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
656000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
508000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8606000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7551000
CY2024Q2 us-gaap Inventory Net
InventoryNet
11224000
CY2023Q4 us-gaap Inventory Net
InventoryNet
10983000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1762000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2987000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
91992000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
112090000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2763000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1763000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1200000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1349000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2024Q2 us-gaap Assets
Assets
95981000
CY2023Q4 us-gaap Assets
Assets
115229000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3516000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1884000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5610000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5980000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9126000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7864000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29319000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29222000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1023000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1160000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1265000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1036000
CY2024Q2 us-gaap Liabilities
Liabilities
40733000
CY2023Q4 us-gaap Liabilities
Liabilities
39282000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21712357
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20879199
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
217000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
209000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
568837000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
553326000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-513596000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-477381000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-210000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-207000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
55248000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
75947000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95981000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115229000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11807000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9500000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22577000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17479000
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
1900000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
1517000
us-gaap Cost Of Revenue
CostOfRevenue
3515000
us-gaap Cost Of Revenue
CostOfRevenue
2845000
CY2024Q2 us-gaap Gross Profit
GrossProfit
9907000
CY2023Q2 us-gaap Gross Profit
GrossProfit
7983000
us-gaap Gross Profit
GrossProfit
19062000
us-gaap Gross Profit
GrossProfit
14634000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2765000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3280000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5822000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6696000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21115000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16455000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
49445000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31852000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
23880000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
19735000
us-gaap Operating Expenses
OperatingExpenses
55267000
us-gaap Operating Expenses
OperatingExpenses
38548000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13973000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11752000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36205000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23914000
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
959000
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
481000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1919000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
721000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
944000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
616000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1988000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1678000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13988000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11617000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36136000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22957000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
79000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
68000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-14029000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11651000
us-gaap Net Income Loss
NetIncomeLoss
-36215000
us-gaap Net Income Loss
NetIncomeLoss
-23025000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
17000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
20000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14029000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11634000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36218000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23005000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21628542
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21628542
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20711850
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20711850
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21430276
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20702589
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
66261000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
67000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
406000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2544000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-1000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-14029000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
55248000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
99642000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
452000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1476000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11651000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
17000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
89964000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
75947000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
882000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
406000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13685000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
546000
us-gaap Net Income Loss
NetIncomeLoss
-36215000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
55248000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
109180000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
156000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
452000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3181000
us-gaap Net Income Loss
NetIncomeLoss
-23025000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
20000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
89964000
us-gaap Profit Loss
ProfitLoss
-36215000
us-gaap Profit Loss
ProfitLoss
-23025000
us-gaap Share Based Compensation
ShareBasedCompensation
13685000
us-gaap Share Based Compensation
ShareBasedCompensation
3181000
us-gaap Depreciation
Depreciation
272000
us-gaap Depreciation
Depreciation
256000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
97000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
73000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1055000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1222000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
241000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3971000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1253000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-689000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1632000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1214000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-154000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-256000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20726000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23057000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1272000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
383000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1272000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-383000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
882000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
156000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
406000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
452000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
546000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
0
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
7500000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
67000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1834000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8041000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20169000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15379000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90569000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106194000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70400000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90815000
us-gaap Interest Paid Net
InterestPaidNet
1613000
us-gaap Interest Paid Net
InterestPaidNet
563000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
4000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p>
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
4511000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4714000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1369000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
654000
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5344000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5615000
CY2024Q2 us-gaap Inventory Net
InventoryNet
11224000
CY2023Q4 us-gaap Inventory Net
InventoryNet
10983000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5823000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4551000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3060000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2788000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2763000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1763000
CY2024Q2 us-gaap Depreciation
Depreciation
141000
CY2023Q2 us-gaap Depreciation
Depreciation
127000
us-gaap Depreciation
Depreciation
272000
us-gaap Depreciation
Depreciation
256000
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1821000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3335000
CY2024Q2 cvrx Accrued Paid Time Off
AccruedPaidTimeOff
1009000
CY2023Q4 cvrx Accrued Paid Time Off
AccruedPaidTimeOff
770000
CY2024Q2 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
560000
CY2024Q2 cvrx Accrued Liabilities Customer Rebate Current
AccruedLiabilitiesCustomerRebateCurrent
450000
CY2023Q4 cvrx Accrued Liabilities Customer Rebate Current
AccruedLiabilitiesCustomerRebateCurrent
411000
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
275000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
220000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
247000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
231000
CY2024Q2 cvrx Clinical Trial And Other Professional Fees
ClinicalTrialAndOtherProfessionalFees
216000
CY2023Q4 cvrx Clinical Trial And Other Professional Fees
ClinicalTrialAndOtherProfessionalFees
277000
CY2024Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
81000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
125000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
951000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
611000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5610000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5980000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
10000000
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
681000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29319000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1200000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1349000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
247000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
231000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1023000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1160000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1270000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1391000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
151000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
350000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
362000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
374000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
223000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1460000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
190000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1270000
CY2024Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P4Y2M12D
CY2024Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.067
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
108406
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
14.92
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4488845
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.77
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
97266000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2732672
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1307400
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.97
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
165987
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.31
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5748130
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.79
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17988000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2906595
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.52
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
13739000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2544000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1476000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13685000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3181000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2544000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1476000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13685000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3181000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
24900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
8400000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
79000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
68000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-14029000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11651000
us-gaap Net Income Loss
NetIncomeLoss
-36215000
us-gaap Net Income Loss
NetIncomeLoss
-23025000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21628542
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20711850
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21430276
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20702589
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5856536
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5225717
CY2024Q2 us-gaap Contractual Obligation
ContractualObligation
0
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
0
CY2024Q2 cvrx Defined Contribution Plan Employer Match Amount
DefinedContributionPlanEmployerMatchAmount
300000
CY2023Q2 cvrx Defined Contribution Plan Employer Match Amount
DefinedContributionPlanEmployerMatchAmount
0
cvrx Defined Contribution Plan Employer Match Amount
DefinedContributionPlanEmployerMatchAmount
600000
cvrx Defined Contribution Plan Employer Match Amount
DefinedContributionPlanEmployerMatchAmount
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11807000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9500000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22577000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17479000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-010719-index-headers.html Edgar Link pending
0001558370-24-010719-index.html Edgar Link pending
0001558370-24-010719.txt Edgar Link pending
0001558370-24-010719-xbrl.zip Edgar Link pending
cvrx-20240630.xsd Edgar Link pending
cvrx-20240630x10q.htm Edgar Link pending
cvrx-20240630xex31d1.htm Edgar Link pending
cvrx-20240630xex31d2.htm Edgar Link pending
cvrx-20240630xex32d1.htm Edgar Link pending
cvrx-20240630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
cvrx-20240630_def.xml Edgar Link unprocessable
cvrx-20240630_lab.xml Edgar Link unprocessable
cvrx-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cvrx-20240630x10q_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cvrx-20240630_cal.xml Edgar Link unprocessable